title: [Current prescription practice of CSE inhibitors at clinic discharge after acute myocardial infarct].
abstract: We investigated the use of statins in clinical practice in patients with acute myocardial infarction in Germany in 17,732 consecutively included patients of the registries MIR-1 and MITRA-1. A clinical follow-up has been performed in the MITRA-1 study after a mean period of 18 months. In total 30% of all patients with acute myocardial infarction received statins at discharge. From 1994 to 1998 the use of statins increased from 6% to 44%; however in 1998 still less than half of the patients with acute myocardial infarction received statins at discharge. In a logistic regression model, concomittant diseases as renal failure (OR 0.7), heart failure (OR 0.7) and diabetes mellitus (OR 0.9) were associated with a lower use of statins. Age > 70 years (OR 0.5) was also associated with a lower use of statins at hospital discharge. Patients with statins at discharge had a lower long-term mortality of 5.8% versus 12.9% in patients without statins. After adjustment to age and comorbidity, use of statins at discharge was associated with a borderline significant reduction of long-term mortality (multivariate OR 0.7, 95% CI 0.4-1.0). In a subgroup analysis of therapeutic benefit, measured by the "number needed to treat" (NNT), the number of patients to treat with statins to save one life, patients with cardiovascular risk factors, as heart failure (NNT 7.5), diabetes mellitus (NNT 7.8) and age > 70 years (NNT 13.8) had a larger therapeutic benefit as patients without these risk factors (NNT 345). However, these high-risk patients received less often statins than patients without risk factors (use of statins 11.8% versus 19.8%).
authors.affiliation: Herzzentrum Ludwigshafen Medizinische Klinik B Bremserstrasse 79 67063 Ludwigshafen, Germany.
authors.forename: H
authors.initials: H
authors.lastname: Wienbergen
authors.forename: R
authors.initials: R
authors.lastname: Schiele
authors.forename: A K
authors.initials: AK
authors.lastname: Gitt
authors.forename: S
authors.initials: S
authors.lastname: Schneider
authors.forename: T
authors.initials: T
authors.lastname: Heer
authors.forename: H
authors.initials: H
authors.lastname: Gohlke
authors.forename: M
authors.initials: M
authors.lastname: Gottwik
authors.forename: R
authors.initials: R
authors.lastname: Thiele
authors.forename: M
authors.initials: M
authors.lastname: Keysser
authors.forename: A
authors.initials: A
authors.lastname: Horsch
authors.forename: A
authors.initials: A
authors.lastname: Weizel
authors.forename: J
authors.initials: J
authors.lastname: Senges
mesh_terms: D000368:Aged; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D004363:Drug Utilization / Q000639:trends; D005260:Female; D005500:Follow-Up Studies; D005858:Germany; D006801:Humans; D006937:Hypercholesterolemia / Q000188:drug therapy* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality; D010351:Patient Discharge; D012042:Registries; D015996:Survival Rate
chemical_list: D000924:Anticholesteremic Agents